Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
11/18/2020 11/19/2020 11/20/2020 11/23/2020 11/24/2020 Date
312.53 310.27 313.53 316.68 318.58 Last
663345 877226 1404832 484922 589738 Volume
+0.37% -0.72% +1.05% +1.00% +0.60% Change
Financials (USD)
Sales 2021 10 120 M - -
Net income 2021 2 245 M - -
Net Debt 2021 4 744 M - -
P/E ratio 2021 47,6x
Yield 2021 0,93%
Sales 2022 10 905 M - -
Net income 2022 2 506 M - -
Net Debt 2022 4 769 M - -
P/E ratio 2022 42,7x
Yield 2022 1,04%
Capitalization 107 B 107 B -
EV / Sales 2021 11,0x
EV / Sales 2022 10,2x
Nbr of Employees 27 000
Free-Float 100,0%
More Financials
Company
CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment... 
More about the company
Notations Surperformance© of CSL Limited
Trading Rating : Investor Rating :
More Ratings
All news about CSL LIMITED
11/17CSL : Urban League, CSL Behring Partner to Address Community Needs including Pub..
AQ
11/15CSL : Australia back on outbreak alert as state virus infections spike
RE
11/15CSL to Invest A$800 Million in Melbourne Vaccine Manufacturing Plant
DJ
11/15CSL : New Vaccine Manufacturing Facility
PU
11/15ASTRAZENECA : Australia to spend $726 mln underwriting country's biggest vaccine..
RE
11/11CSL : Behring to Present New Real-World Data on Outcomes Following Acute Coronar..
AQ
11/10CSL : Appendix 2A
PU
11/08CSL : Commences Manufacturing Of University Of Oxford/Astrazeneca Vaccine Candid..
RE
11/08CSL : University of Oxford/AstraZeneca Vaccine Candidate
PU
11/05India sees early vaccine launch as AstraZeneca deliveries run late
RE
11/05Australia shares rise on likelihood of divided U.S. Congress
RE
11/05Australia orders more COVID-19 vaccines for total of 135 million doses
RE
11/05Australia orders more COVID-19 vaccines for total of 135 million doses
RE
11/05Australian shares rise as U.S. election results roll in
RE
11/04Australia signs two more COVID-19 vaccine deals
RE
More news
News in other languages on CSL LIMITED
09/04TOUR DU MONDE DES INDICES : Verdissement de la finance et voyage au pays des kan..
08/14CSL LIMITED : publication des résultats annuels
08/14CSL LIMITED : Veröffentlichung des Jahresergebnisses
06/17LONDON STOCK EXCHANGE : Londres ouvre en hausse
06/17STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 225,30 $
Last Close Price 234,67 $
Spread / Highest target 6,99%
Spread / Average Target -3,99%
Spread / Lowest Target -22,3%
EPS Revisions
Managers
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Brian Anthony McNamee Chairman
Paul McKenzie Chief Operating Officer
Joy Carolyn Linton Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer & Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED15.53%106 562
SAMSUNG BIOLOGICS CO.,LTD.85.22%47 754
BIOGEN INC.-18.29%37 318
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.148.61%29 969
ALEXION PHARMACEUTICALS, INC.13.37%26 942
UCB28.43%20 443